Home Biotechnology Industry News
Biotechnology industry news, updates, and press releases

As stringent new budgets have led to pharmaceutical companies cutting back, a certain concern and scepticism has risen over the high prices charged by drug companies, their continued problems with productivity, and falling success rates of new drugs. A significant drop in investment in drugmaking companies, and president Obama’s recent reforms of the healthcare system in the USA, feel like a precursor to change in a sector that traditionally relies on older products and philosophies, rather than innovating.

In a recent issue of the Journal of Generic Medicines, world-renowned economist Joseph Stiglitz and economics professor and Roosevelt Institute fellow Arjun Jayadev examine pharmaceutical R&D from a fresh economic perspective.

Stiglitz and Jayadev put forward the argument that current models of pharmaceutical drug discovery have major inefficiencies, and suggest four different policies to address them. They propose meaningful, realistic plans and pricing models to minimise costs to the public sector, maximise positive social impact and remedy the irrationalities in the current system.

Progressive and unafraid of controversy, the article’s arguments for how to improve pharmaceutical R&D are a must-read for anyone in the industry, as well as academics, policy-makers, stakeholders and members of government.

The article is available on the Journal of Generic Medicines website.

New Reports Based on Data-Mining the DrugPatentWatch database

Please contact us with any special data requirements beyond the existing report catalog

Orphan Drug Report

The Orphan Drug Report profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity

The Report includes:

  • The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
  • Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
  • All FDA-listed patents covering each Orphan Drug

Report highlights:

  • More than 100 pages
  • More than 80 drugs profiled

More information is available at http://www.thinkpharm.com/orphan-drug-report.html

Drug Patent Challenge Report

The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drugs patents.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

  • A list of the companies with the most successful patent challenges
  • A list of all the drugs for which each firm successfully challenged a patent
  • A list of all the companies that have received FDA approval for each listed drug

Report Highlights:

  • More than 60 companies profiled
  • More than 80 drugs profiled

More information is available at http://www.thinkpharm.com/drug-patent-challenge-report.html

Drug Patent Inventor Report

The Drug Patent Inventor Report profiles the individuals, US states, and countries leading pharmaceutical innovation.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

  • Top Inventors
      Which inventors were granted the most patents?
  • Patents per Inventor
      The patents awarded to each inventor
  • Approved Drugs per Inventor
      The approved drugs protected by each inventor’s patents
  • Co-Inventors per Inventor
      The co-inventors listed on each inventor’s patents
  • Assignees per Inventor
      The assignees listed on each inventor’s patents
  • Inventors per US State
      A count of the number of inventors in each state, along with the number of patents awarded to each inventor
  • Inventors per Country
      A count of the number of inventors in each country, along with the number of patents awarded to each inventor

Data highlights

  • More than 3,000 pages
  • More than 4,000 inventors listed
  • More than 2,000 patents listed
  • 44 US states listed
  • 30 countries listed

More information is available at http://www.thinkpharm.com/drug-patent-inventor-report.html

Kraig Biocraft Laboratories, Inc. (OTC.BB:KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.

“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”

In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month. Earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

HealthBank empowering patients with full ownership and control of their stored tumor tissue integral for tailored treatment courses; Six-year brain tumor survivor Bob Gibbs exemplifies the importance of banking tumor tissue for personalized cancer vaccines, which saved his own life

Here’s something to wrap your brain around: tumors saves lives!  Few cancer patients realize that tumor tissue is a precious information source that can play a critical role in fighting cancer if – and only if – it is saved at the time of surgery, and properly stored for human use rather than just lab testing.

This because correctly banked tumor tissue can be used for the creation of personalized immune therapies tailored for each patient’s unique tumor profile or “fingerprint,” like the DCVax personalized cancer vaccine from Northwest Biotheraputics (OTCBB:NWBO) that saved the life of Bob Gibbs – now a 6 year survivor of a lethal Grade 3 brain tumor.

“Unfortunately, most cancer patients don’t realize tumor banking services are available, the magnitude of this choice, and critical differences between the types of bio banks in existence,” said Linda Powers, chairman of HealthBank – the only bio bank in the U.S. FDA certified as an eligible (“cGMP”) facility for the production and storage of cells for human use..

With Bob’s notable 6 years of survival from a disease that’s effectively an immediate death sentence, he exemplifies the importance of tumor banking for the hundreds of thousands of terminally-ill cancer patients who now have hope for a longer and brighter future…but unfortunately don’t even know it.  “Such tumor banking services for patients have been available in Japan and Germany for years, but is a new opportunity for patients in the U.S. with HealthBank’s FDA certification,” Gibbs notes.

To help expand patient knowledge about, and access to, tumor banking and related medical treatments, Bob has established Miles for Hope (www.MilesforHope.com), a non-profit organization dedicated to raising awareness about brain and other cancer tissue banking and funds to support the cause. Bob’s heroic crusade to educate patients about tumor tissue banking and emerging immunotherapies – even as he battles his own medical issues – personifies selflessness and offers a highly compelling human interest story in this regard.

More information about HealthBank and its services may be accessed online at www.HealthBank.com. View a recent and related press release by Miles for Hope here: http://tinyurl.com/tumorbanking and compelling 5-minute docu-footage of Bob and his physician discussing tumor banking and the DCVax treatment here: http://www.youtube.com/watch?v=n1tCQjoCrOM. Learn more about the DCVax custom cancer vaccine here: www.kerncomm.com/CustomVaccine.doc.

Compound registration, structure search and computed properties rolled out.

Budapest, Hungary and Cambridge, Massachusetts, 19 August 2010 – ChemAxon, a leading provider of chemistry software for life sciences, announced today that they have entered into an agreement with the Broad Institute of Harvard and MIT, which will license ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use. Broad will support their legacy small molecule registration system and other functionality across their Chemical Biology Platform with ChemAxon’s technology.

In addition to ChemAxon’s discovery and desktop tools, the Broad Institute has already updated their core technology for archiving small molecules by deploying the JChem platform toolkit within their existing system.

“This adoption is a part of our strategy to provide our scientists in the Chemical Biology Platform with the most modern and capable tools to accelerate our research,” said Michael Foley, Director of the Broad’s Chemical Biology Platform. “The extensive capabilities of the ChemAxon software support our ongoing efforts to build and apply state of the art facilities to support our work.”

The evaluation and deployment is to be presented during ChemAxon’s User Group Meeting being held in Boston’s Omni Parker House, September 14-15, the complete program is here:  http://www.chemaxon.com/events/2010-us-ugm/

About ChemAxon
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit www.chemaxon.com.

Ness Ziona, Israel –  17 August 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a universal influenza vaccine, today announced that it has received the approvals of the Ethics (“Helsinki”) Committees of the Institutional Review Boards (IRB) of both the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem (“Hadassah”) and the Tel Aviv Sourasky Medical Center (“Ichilov”), to perform a Phase II clinical trial to evaluate the safety and immunogenicity of BiondVax’s universal influenza vaccine candidate, the Multimeric-001.

Both Hadassah and Ichilov are internationally recognized medical facilities that have vast experience in the conduct of clinical trials.  The principal investigators conducting the clinical trial will be Prof. Yoseph Caraco, Director of the Clinical Research Center at Hadassah and Dr. Jacob Atsmon, Director of the Clinical Research Center at Ichilov.

The trial is designed to include a total of 160 participants, both male and female, 18-49 years old, who will be divided into three groups: a treatment group of 80 participants that will receive the 500mcg adjuvanted formulation of the Multimeric-001 vaccine, and two control groups of 40 participants each, that will receive adjuvanted and non-adjuvanted placebo formulations, respectively.

Screening of the potential participants will commence immediately, with the first administrations of the vaccine expected to take place in October 2010.  The Company expects to be able to report headline results from this trial by the end of the second quarter of 2011.

Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientific Officer, said, “We are very pleased to have received the necessary approvals for the initiation of our first Phase II clinical trial.  We are looking forward to commencing the trial in October, and to continuing our progress towards the successful development of the world’s first truly universal influenza vaccine.”

For further information, please contact:
Danny Aronovic

Public Relations Consultant

GKS Marketing

Tel: +972-98995813

Mob: +972-507991121


About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains and pandemic influenza strains, such as Swine flu and Avian flu.

BiondVax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

BiondVax has recently successfully concluded two Phase I/II clinical trials for the Multimeric-001 vaccine.  The vaccine was shown to be safe and immunogenic in both trials.  The first Phase II clinical trial is scheduled to commence in the second half of 2010.

For further information on BiondVax, please visit www.biondvax.com